• Subscribe
  • Newsfeed
  • About
Announce News

Neurovalens

To add a bio or update company history, please click update information.

News from Neurovalens

    Neurovalens secures £6m in funding led by Investment Fund for Northern Ireland to expand non-invasive neuro-technologyNeurovalens secures £6m in funding led by Investment Fund for Northern Ireland to expand non-invasive neuro-technology
    Neurovalens
    19 Aug 2025

    Neurovalens secures £6m in funding led by Investment Fund for Northern Ireland to expand non-invasive neuro-technology

    Neurovalens designs non-invasive neurostimulation devices that treat conditions such as insomnia and anxiety, using wearable technology cleared for clinical use.

Neurovalens
  • Health
  • Belfast, United Kingdom
  • £6m
  • neurovalens.com
  • Update Information

More venture news

  • Tetra secures a £450k pre-seed round from angels for surgical scheduling software for hospitals
    Tetra
    26 Feb 2026

    Tetra secures a £450k pre-seed round from angels for surgical scheduling software for hospitals

    Pre-seedHealth
  • Eco-Inject lands £5.2m in funding led by Adjuvo to simplify how patients self-inject treatments with a bio-based autoinjector
    Eco-Inject
    23 Feb 2026

    Eco-Inject lands £5.2m in funding led by Adjuvo to simplify how patients self-inject treatments with a bio-based autoinjector

    EquityHealth
  • Nul announces its £740k seed round led by dmg ventures and BYVP to reduce alcohol consumption with its telehealth platform
    Nul
    17 Feb 2026

    Nul announces its £740k seed round led by dmg ventures and BYVP to reduce alcohol consumption with its telehealth platform

    Pre-seedHealth

Sign-up to our newsletter

The UK Weekly email covers every VC round from last week, firms that are hiring, and much more

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn

Announce

  • Share your story

General

  • Read the latest
  • About Soapbox

Information not up to date?

Get in touch

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn